453 results on '"Steg, P. G."'
Search Results
2. Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES
3. Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT
4. Current use of antiplatelet therapy in the management of acute myocardial infarction: overview of the FRENCHIE national registry
5. Impact of transfusion on platelet aggregation and biomarkers in myocardial infarction patients with anemia: an ancillary study of the randomized REALITY trial
6. New-onset atrial fibrillation in chronic coronary syndrome outpatients. Insights from the international CLARIFY registry
7. Standard modifiable risk factors and mortality in patients with ST-segment elevation myocardial infarction: findings from the FRENCHIE cohort
8. Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT
9. Design of knowledge-based mechanistic model of atherosclerotic cardiovascular disease for in silico trials
10. Effect of a restrictive vs. liberal blood transfusion strategy among patients with acute myocardial infarction and anemia according to heart failure. A subgroup analysis of the REALITY trial
11. Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF
12. A Tale of Two Countries: Costs and Financial Incentives for Provisional Stenting during Percutaneous Coronary Intervention in France and the United States
13. Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial
14. Abbreviated dual antiplatelet therapy after PCI in patients at high bleeding risk: a collaborative meta-analysis of randomized trials
15. Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS
16. Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial
17. Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial
18. Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking
19. Safety and efficacy of biodegradable polymer biolimus-eluting stents in patients with non-ST-elevation acute coronary syndrome: a pooled analysis of GLASSY and TWILIGHT
20. Prevalence and determinants of sleep apnea in the French general population
21. Quelle place pour les nouveaux anti-agrégants plaquettaires dans la stratégie thérapeutique ?
22. Facteurs de risque de complications digestives des patients sous antiagrégant plaquettaire suivis en cardiologie de ville : description et prise en charge
23. Supplement to: Ivabradine in stable coronary artery disease without clinical heart failure.
24. Supplement to: Bivalirudin started during emergency transport for primary PCI.
25. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings
26. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry
27. Use of drug eluting stents: expert consensus of the French Society of Cardiology
28. La péricardite aiguë en 2007 : un défi diagnostique
29. P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary intervention
30. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial†
31. Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries
32. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial†
33. PROGNOSIS OF CEREBRAL INFARCTION ACCORDING TO CORONARY ARTERY DISEASE STATUS: 3
34. P34 The effect of sex on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCI trial
35. Two-year vascular event rates in patients with cerebrovascular disease: the reach registry: PO20389
36. Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease
37. P6510Frailty and in-hospital outcomes in percutaneous coronary interventions
38. P2817Efficacy and safety of ticagrelor monotherapy in patients with complex percutaneous coronary intervention: insights from the Global Leaders trial
39. 3294Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY registry
40. P6408Potential benefit of ticagrelor monotherapy for patients with hypertension undergoing percutaneous coronary intervention: insights from the Global Leaders trial
41. P6411Dyspnea in ticagrelor treated patients in the all-comer randomized GLOBAL LEADERS study and its association with clinical outcomes
42. 2211Prevalence, incidence and prognostic implications of left bundle branch block in patients with stable coronary artery disease. an analysis from the CLARIFY registry
43. P2811Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: insights from the Global Leaders trial
44. P5010Use of risk score to identify lower and higher risk subsets among COMPASS-Eligible patients with stable CAD. Insights from the CLARIFY Registry
45. 4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment
46. P1226Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES
47. P2812Ischemic efficacy and bleeding safety of ticagrelor monotherapy in patients with multivessel percutaneous coronary intervention: insights from the Global Leaders trial
48. P2531Impact of age on clinical outcomes after PCI in patients with ACS and stable CAD treated with 23-month ticagrelor monotherapy following 1-month DAPT in the randomized GLOBAL LEADERS study
49. P4752Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
50. 2387Recurrent cardiovascular events and mortality in relation to antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (MINOCA)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.